These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2018-003998-96 A Phase II, single arm Study of avelumab In combination with Axitinib in Patients With unresectable/metastatic Gastrointestinal Stromal Tumor after failure of standard therapy - AXAGIST not-yet-due
Completed, but no date Terminated 2019-004010-34 Assessment of tolerance and spread of the whole body at myeloablative doses in association with cladribine before allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia ... bad-data
Exempt 2021-003762-13 PHASE 1B/2 STUDY OF LIPOSOMAL ANNAMYCIN (L-ANNAMYCIN) IN PATIENTS WITH PREVIOUSLY TREATED SOFT-TISSUE SARCOMAS WITH METASTASES (ANNA-SARC) not-yet-due
Other 2022-000494-91 A multicentre, open-label phase 2 study to evaluate the efficacy and safety of pembrolizumab in the treatment of advanced, progressive adrenocortical carcinoma. not-yet-due
Other 2022-003845-36 A Phase II, single-arm clinical trial evaluating efficacy and safety of pembrolizumab in combination with a soluble LAG-3 protein, eftilagimod alpha, and radiotherapy in neoadjuvant treatment of patie... not-yet-due